Showing 2731-2740 of 5621 results for "".
- UK to Test “Subscription-Style” Payment Model in Effort to Spur Development of New Antibioticshttps://modernod.com/news/uk-to-test-subscription-style-payment-model-in-effort-to-spur-development-of-new-antibiotics/2476717/The NHS will test a “subscription-style” payment model for antibiotics as part of efforts by the UK government to incentivise companies to develop new medicines to tackle drug-resistant infections. Under the proposed scheme, the Department of Health and Social Care said Tuesday that d
- Wize Pharma Enters Joint Venture With Cannabics Pharmaceuticals to Develop Cannabinoid Ophthalmic Treatmentshttps://modernod.com/news/wize-pharma-enters-joint-venture-with-cannabics-pharmaceuticals-to-develop-cannabinoid-ophthalmic-treatments/2476713/Israel-based Wize Pharma and Cannabics Pharmaceuticals have together created and adopted a business plan for a joint venture focused on the research and development of cannabinoid formulations to treat ophthalmic conditions. Creation and approval of a business plan for the joint venture was a con
- Zeiss Receives FDA Clearance for Clarus 700 Ultra-Widefield Imaging Devicehttps://modernod.com/news/zeiss-receives-fda-clearance-for-clarus-700-ultra-widefield-imaging-device/2479571/Zeiss announced that it has received FDA 510(K) clearance for the Clarus 700, high-definition, ultra-widefield imaging system. Clarus 700 is the first high-resolution ultra-widefield imaging with true color and a comp
- EyePoint Pharmaceuticals Announces US Commercialization of Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-us-commercialization-of-dexycu/2479573/EyePoint Pharmaceuticals announced the commercial launch of Dexycu (dexamethasone intraocular suspension) 9% in the United States. Dexycu is the first and only FDA approved intraocular steroid for the treatment of postoperative inflammation and is administered as
- Hoya Surgical Optics Obtains CE Mark for Nanex multiSert+ IOL Delivery Systemhttps://modernod.com/news/hoya-surgical-optics-obtained-ce-mark-for-nanex-multisert-iol-delivery-system/2476708/Hoya Surgical Optics has obtained CE Mark for Nanex multiSert+, which consists of a a new IOL delivered in a first-of-its kind preloaded delivery system, according to a company news release. The 1.62 mm injector tip of multiSert+ is the world’s smallest nozzle size in
- Ocular Therapeutix Announces Commercial Launch of Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-commercial-launch-of-dextenza/2476704/Ocular Therapeutix announced the commercial launch in the United States of Dextenza (dexamethasone ophthalmic insert) 0.4 mg for the treatment of ocular inflammation and pain following ophthalmic surgery. Dextenza is the first FDA-approved intracanalicular insert that enables the delivery of drug
- VSP Global Enters Into Definitive Agreement To Acquire Visionworkshttps://modernod.com/news/vsp-global-enters-into-definitive-agreement-to-acquire-visionworks/2476699/VSP Global announced that it has entered into a definitive agreement to acquire San Antonio, Texas-based Visionworks, which has more than 700 stores in 40 states. The Visionworks acquisition will be the single largest VSP network investment in the company’s
- AbbVie to Buy Allergan in Deal Worth $63 Billionhttps://modernod.com/news/abbvie-to-buy-allergan-in-deal-worth-63-billion/2476686/A blockbuster merger of two large pharma companies will have an impact on the eye care market as AbbVie announced its plans to buy Allergan in a deal worth $63 billion. Under the agreed terms, Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each share they h
- Alnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Deliveryhttps://modernod.com/news/alnylam-announces-progress-with-rnai-therapeutics-platform-including-oral-route-of-administration-and-cns-and-ocular-delivery/2476682/Alnylam Pharmaceuticals announced new advances in its RNAi therapeutics platform, including preclinical results demonstrating oral delivery of GalNAc-conjugated small interfering RNAs (siRNAs) – the molecules that mediate RNAi – directed to a liver target. Oral delivery could broaden the clinical
- Ocular Therapeutix Receives FDA Approval of Supplemental NDA for Dextenza for Postoperative Ocular Inflammationhttps://modernod.com/news/ocular-therapeutix-receives-fda-approval-of-supplemental-nda-for-dextenza-for-the-treatment-of-ocular-inflammation-following-ophthalmic-surgery/2476680/Ocular Therapeutix announced the FDA approved a supplemental new drug application (NDA) for Dextenza to include the treatment of ocular inflammation following ophthalmic surgery as an additional indication. With the approval of the supplemental NDA, Dextenza is now approved for the treatment of b